Abscopal Effect from Low-dose Radiotherapy in Metastatic Cancer Combined with Stereotactic Body Radiotherapy

NANot yet recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

December 31, 2026

Conditions
NeoplasmsSecondary Malignant Neoplasm
Interventions
RADIATION

SBRT + LDRT

"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV."

RADIATION

SBRT alone

"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions."

All Listed Sponsors
collaborator

SMG-SNU Boramae Medical Center

OTHER

lead

Soonchunhyang University Hospital

OTHER

NCT05578274 - Abscopal Effect from Low-dose Radiotherapy in Metastatic Cancer Combined with Stereotactic Body Radiotherapy | Biotech Hunter | Biotech Hunter